U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.
Bristol-Myers Squibb Co. inked a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2 billion, as the US drugmaker seeks to leverage China’s efficiency in early development.
